{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:56:25Z","timestamp":1787165785653,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1136\/ard.2008.091462","type":"journal-article","created":{"date-parts":[[2008,7,16]],"date-time":"2008-07-16T21:49:24Z","timestamp":1216244964000},"page":"892-897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":148,"title":["A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300\u2013600 mg\/day versus benzbromarone 100\u2013200 mg\/day in patients with gout"],"prefix":"10.1016","volume":"68","author":[{"given":"M K","family":"Reinders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Haagsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T L Th A","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E N","family":"van Roon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Delsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A F J","family":"van de Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J R B J","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2008.091462_bib1","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II. management","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.091462_bib2","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2008.091462_bib3","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/ard.2007.085902","article-title":"Survey among Dutch rheumatologists on management of gout","volume":"67","author":"Reinders","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.091462_bib4","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/rheumatology\/kel071","article-title":"Effectiveness of interventions for the treatment of acute and prevention of recurrent gout: a systematic review","volume":"45","author":"Sutaria","year":"2006","journal-title":"Rheumatology"},{"key":"10.1136\/ard.2008.091462_bib5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/0003-4819-64-2-229","article-title":"Allopurinol in the treatment of gout","volume":"64","author":"Rundles","year":"1966","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2008.091462_bib6","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1161\/CIRCULATIONAHA.106.651117","article-title":"High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid","volume":"114","author":"George","year":"2006","journal-title":"Circulation"},{"key":"10.1136\/ard.2008.091462_bib7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.2007.083071","article-title":"Efficacy and tolerability of urate lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol","volume":"68","author":"Reinders","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.091462_bib8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","article-title":"Pathogenesis of gout","volume":"143","author":"Choi","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2008.091462_bib9","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/ard.2006.063768","article-title":"Are joints affected by gout also affected by osteoarthritis?","volume":"66","author":"Roddy","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.091462_bib10","first-page":"684","article-title":"Gouty arthritis in nodal osteoarthritis","volume":"23","author":"Fam","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.091462_bib11","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMcp030733","article-title":"Gout","volume":"349","author":"Terkeltaub","year":"2003","journal-title":"N Engl Med J"},{"key":"10.1136\/ard.2008.091462_bib12","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1001\/jama.289.21.2857","article-title":"Gout","volume":"289","author":"Rott","year":"2003","journal-title":"JAMA"},{"key":"10.1136\/ard.2008.091462_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/01.bor.0000162060.25895.a5","article-title":"Recent advances in the management of gout and hyperuricemia","volume":"17","author":"Wortmann","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard.2008.091462_bib14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/art.1780150209","article-title":"The influence of temperature on the solubility of monosodium urate","volume":"15","author":"Loeb","year":"1972","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.091462_bib15","first-page":"577","article-title":"Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?","volume":"28","author":"Li-Yu","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.091462_bib16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.091462_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","article-title":"Serum urate levels and gout flares: analysis from managed care data","volume":"12","author":"Sarawate","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"10.1136\/ard.2008.091462_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-4615-5381-6_3","article-title":"Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment","volume":"431","author":"Yamanaka","year":"1998","journal-title":"Adv Exp Med Biol"},{"key":"10.1136\/ard.2008.091462_bib19","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.091462_bib20","doi-asserted-by":"crossref","first-page":"756","DOI":"10.7326\/0003-4819-131-10-199911160-00007","article-title":"Synovial fluid analysis for diagnosis of intercritical gout","volume":"131","author":"Pascual","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2008.091462_bib21","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","article-title":"Preliminary criteria for the classification of the acute arthritis of primary gout","volume":"20","author":"Wallace","year":"1977","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.091462_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1136\/ard.2008.091462_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1136\/ard.2008.091462_bib24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0002-9343(90)90097-W","article-title":"Uric acid handling in autosomal dominant polycystic kidney disease with normal filtration rates","volume":"89","author":"Kaehny","year":"1990","journal-title":"Am J Med"},{"key":"10.1136\/ard.2008.091462_bib25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1136\/ard.2008.091462_bib26","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/1541-0420.00051","article-title":"A cautionary note on exact unconditional inference for a difference between two independent binomial proportions","volume":"59","author":"Mehrotra","year":"2003","journal-title":"Biometrics"},{"key":"10.1136\/ard.2008.091462_bib27","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/00031305.2000.10474560","article-title":"Simple and effective confidence intervals for proportions and differences of proportions result from adding two successes and two failures","volume":"54","author":"Agresti","year":"2000","journal-title":"Am Stat"},{"key":"10.1136\/ard.2008.091462_bib28","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","article-title":"Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout","volume":"57","author":"Perez-Ruiz","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.091462_bib29","first-page":"S40","article-title":"Efficacy of benzbromarone compared to allopurinol in lowering serum urate level in hyperuricemic patients","volume":"85","author":"Hanvivadhanakul","year":"2002","journal-title":"J Med Assoc Thai"},{"key":"10.1136\/ard.2008.091462_bib30","unstructured":"Dutch Practitioners Guidelines. Gout. 2nd edn. 2004. http:\/\/nhg.artsennet.nl\/static\/images\/nhg\/upload\/104\/standaarden\/M72\/start.htm (accessed 30 Mar 2009)."},{"key":"10.1136\/ard.2008.091462_bib31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0021-9258(18)56440-1","article-title":"The fate of uric acid in man","volume":"183","author":"Geren","year":"1949","journal-title":"J Biol Chem"},{"key":"10.1136\/ard.2008.091462_bib32","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2008.091462_bib33","first-page":"1575","article-title":"Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims","volume":"31","author":"Riedel","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.091462_bib34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/RHU.0b013e318164dceb","article-title":"Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease","volume":"14","author":"Panomvana","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"10.1136\/ard.2008.091462_bib35","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23007","article-title":"Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?","volume":"57","author":"Perez-Ruiz","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.091462_bib36","first-page":"701","article-title":"Ten years\u2019 experience with benzbromarone in the management of gout and hyperuricaemia","volume":"59","author":"Masbernard","year":"1981","journal-title":"S Afr Med J"},{"key":"10.1136\/ard.2008.091462_bib37","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2165\/00002018-199411040-00004","article-title":"Risks and benefits of drugs used in the management and prevention of gout","volume":"11","author":"Conaghan","year":"1994","journal-title":"Drug Saf"},{"key":"10.1136\/ard.2008.091462_bib38","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1021\/tx7001228","article-title":"Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate","volume":"20","author":"McDonald","year":"2007","journal-title":"Chem Res Toxicol"},{"key":"10.1136\/ard.2008.091462_bib39","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2165\/00003495-200464210-00003","article-title":"Management of acute and chronic gouty arthritis: present state-of-the-art","volume":"64","author":"Schlesinger","year":"2004","journal-title":"Drugs"},{"key":"10.1136\/ard.2008.091462_bib40","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1056\/NEJMe058247","article-title":"Febuxostat: treatment for hyperuricemia and gout?","volume":"353","author":"Moreland","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2008.091462_bib41","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10067-006-0528-3","article-title":"Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients","volume":"26","author":"Reinders","year":"2007","journal-title":"Clin Rheum"},{"key":"10.1136\/ard.2008.091462_bib42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1524-4733.2007.00173.x","article-title":"The impact of gout on work absence and productivity","volume":"10","author":"Kleinman","year":"2007","journal-title":"Value Health"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724217581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724217581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2008.091462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T01:55:18Z","timestamp":1737510918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724217581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0003496724217581"],"URL":"https:\/\/doi.org\/10.1136\/ard.2008.091462","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300\u2013600 mg\/day versus benzbromarone 100\u2013200 mg\/day in patients with gout","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2008.091462","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 2009 Published by Elsevier Inc. Publishing Group and European League Against Rheumatism. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}